Earnings Preview: Bristol-Myers 3Q earnings report

Earnings Preview: Bristol-Myers 3Q earnings report
merit.’ Meanwhile, she said investor focus remains on cost savings, sales of four growth driversPlavix, Orencia for rheumatoid arthritis, leukemia drug Sprycel and combination HIV drug Atriplaalong with some key drugs in development. Those include the
Source: c.moreover.com

Comments are closed.